ambrisentan

• “Due to competitive concerns with Myogen's ambrisentan, which is expected to enter the market in 2007, timing is of the essence for Encysive.”

  Forbes: Encysive Shares Clouded By Uncertainty

• “Gilead has a medicine called ambrisentan for the same lung disease in the final stage of human testing generally required for regulatory approval.”

  Gilead to Buy Arresto Biosciences for $225 Million to Obtain Lung Medicine - Bloomberg

• “Data on ambrisentan, however, has been very promising; many analysts think the drug can take on Actelion's similar Tracleer.”

  Forbes: Gilead's Big Shift

• “Myogen's lead drug, ambrisentan, is a treatment for a rare disease called pulmonary arterial hypertension, PAH, a blood pressure disorder of the lungs that makes it extremely difficult for patients to breathe.”

  Forbes: Gilead's Big Shift

• “GlaxoSmithKline, which markets Flolan, the current standard-of-care treatment, obtained non-U.S. marketing rights for Myogen's ambrisentan last March in exchange for U.S. rights for Flolan.”

  Forbes: Gilead's Big Shift

• “Myogen's lead drug candidate is ambrisentan, a new type of treatment for pulmonary arterial hypertension, a blood pressure disorder of the lungs.”

  Forbes: Buyouts Lift Biotechs

• “Understanding the function of the lung could help in developing other drugs that might fit in with Cayston and ambrisentan.”

  Forbes: Gilead's Big Shift

• “Shares of Myogen fell 10% as investors were disappointed with a recently announced deal with British drug giant GlaxoSmithKline for experimental drug ambrisentan, a treatment for pulmonary arterial hypertension.”

  Forbes: Tysabri News Lifts Drug Stocks

• “Separately, Myogen said it forged an alliance with British drug giant GlaxoSmithKline for experimental drug ambrisentan, a treatment for pulmonary arterial hypertension.”

  Forbes: Eye On Stocks For Tuesday, March 7, 2006Eye On Stocks For Tuesday, March 7

• “We are maintaining our 'hold' rating, as we expect near-term weakness driven by visibility on Myogen's ambrisentan and a potentially slow launch due to the wide acceptance of Pfizer's Revatio," the firm said.”

  Forbes: Eye On Stocks For Friday, March 24, 2006 Eye On Stocks For Friday, March 24

Show 10 more examples...